应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01530 三生制药
未开盘 12-19 16:08:47
6.100
-0.040
-0.65%
最高
6.170
最低
6.000
成交量
438.56万
今开
6.170
昨收
6.140
日振幅
2.77%
总市值
146.13亿
流通市值
146.13亿
总股本
23.96亿
成交额
2,663万
换手率
0.18%
流通股本
23.96亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
三生制药12月19日遭主力抛售276万元 环比增加200.00%
市场透视 · 12-19 16:15
三生制药12月19日遭主力抛售276万元 环比增加200.00%
三生制药(01530)注销库存股份
智通财经 · 12-18 18:48
三生制药(01530)注销库存股份
三生制药12月18日主力资金流出92万元 连续3日减仓
市场透视 · 12-18 16:15
三生制药12月18日主力资金流出92万元 连续3日减仓
南向资金12月16日净卖出三生制药192.90万股 连续3日减持
市场透视 · 12-17 09:30
南向资金12月16日净卖出三生制药192.90万股 连续3日减持
三生制药12月12日遭主力抛售940万元 环比增加900.00%
市场透视 · 12-12
三生制药12月12日遭主力抛售940万元 环比增加900.00%
三生制药12月6日遭南向资金减持586.75万股
市场透视 · 12-09
三生制药12月6日遭南向资金减持586.75万股
三生制药12月5日遭南向资金减持776.20万股
市场透视 · 12-06
三生制药12月5日遭南向资金减持776.20万股
《大行》招商国际微升三生制药(01530.HK)目标价至9.81元 创新品种蓄势待发
阿斯达克财经 · 12-05
《大行》招商国际微升三生制药(01530.HK)目标价至9.81元 创新品种蓄势待发
【券商聚焦】招银国际升三生制药(01530)目标价至9.81港元 料特比澳持续快速增长
金吾财讯 · 12-05
【券商聚焦】招银国际升三生制药(01530)目标价至9.81港元 料特比澳持续快速增长
招财日报2024.12.5 Salesforce及三生制药公司点评
招银国际 · 12-05
招财日报2024.12.5 Salesforce及三生制药公司点评
南向资金12月4日净买入三生制药77.60万股 连续3日增持
市场透视 · 12-05
南向资金12月4日净买入三生制药77.60万股 连续3日增持
三生制药(01530)出现大手卖出78.2万股,成交价$6.36,涉资497.352万
阿斯达克财经 · 12-04
三生制药(01530)出现大手卖出78.2万股,成交价$6.36,涉资497.352万
三生国健:三生制药及其下属企业持有公司的股份数并未发生变化
证券之星 · 12-03
三生国健:三生制药及其下属企业持有公司的股份数并未发生变化
【券商聚焦】招银国际:多款重磅国产创新药纳入医保 基金收支有望改善
金吾财讯 · 12-03
【券商聚焦】招银国际:多款重磅国产创新药纳入医保 基金收支有望改善
三生制药(01530)上涨10.02%,报6.37元/股
金融界 · 12-03
三生制药(01530)上涨10.02%,报6.37元/股
招银国际:医保持续支持创新 基金收支有望改善
智通财经 · 12-03
招银国际:医保持续支持创新 基金收支有望改善
招商证券:维持三生制药(01530)“增持”评级 目标价上调至11港元
智通财经 · 12-03
招商证券:维持三生制药(01530)“增持”评级 目标价上调至11港元
三生制药早盘涨超5% 长江证券首次覆盖给予“增持”评级
新浪港股 · 12-03
三生制药早盘涨超5% 长江证券首次覆盖给予“增持”评级
三生制药盘中异动 快速上涨5.01%报6.080港元
市场透视 · 12-03
三生制药盘中异动 快速上涨5.01%报6.080港元
港股异动 | 三生制药(01530)现涨近5% 机构预计特比澳国谈续约结果温和 丽美治成功纳入医保目录
智通财经 · 12-03
港股异动 | 三生制药(01530)现涨近5% 机构预计特比澳国谈续约结果温和 丽美治成功纳入医保目录
加载更多
公司概况
公司名称:
三生制药
所属市场:
SEHK
上市日期:
--
主营业务:
三生制药是一家主要从事开发、生产、营销及销售医药产品的投资控股公司。该公司的主要产品包括重组人血小板生成素产品,肿瘤坏死因子α抑制剂产品以及重组人促红素等。产品以特比澳,益赛普,益比奥,以及赛博尔等品牌销售。该公司在国内市场和斯里兰卡、多米尼加共和国及泰国等海外市场销售产品。该公司的子公司包括集思有限公司,香港三生医疗有限公司和沈阳三生制药有限责任公司。该公司通过其子公司还从事项目管理及咨询业务。
发行价格:
--
{"stockData":{"symbol":"01530","market":"HK","secType":"STK","nameCN":"三生制药","latestPrice":6.1,"timestamp":1734595727013,"preClose":6.14,"halted":0,"volume":4385579,"delay":0,"floatShares":2395573912,"shares":2395573912,"eps":0.68140924,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.04,"latestTime":"12-19 16:08:47","open":6.17,"high":6.17,"low":6,"amount":26633931,"amplitude":0.027687,"askPrice":6.1,"askSize":139000,"bidPrice":6.09,"bidSize":11500,"shortable":3,"etf":0,"ttmEps":0.7308787944822009,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734658200000},"adr":0,"adjPreClose":6.14,"dividendRate":0.039907,"openAndCloseTimeList":[[1734571800000,1734580800000],[1734584400000,1734595200000]],"volumeRatio":0.487675,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01530","defaultTab":"news","newsList":[{"id":"2492141037","title":"三生制药12月19日遭主力抛售276万元 环比增加200.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492141037","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492141037?lang=zh_cn&edition=full","pubTime":"2024-12-19 16:15","pubTimestamp":1734596121,"startTime":"0","endTime":"0","summary":"12月19日, 三生制药股价跌0.65%,报收6.10元,成交金额2663万元,换手率0.18%,振幅2.77%,量比0.49。三生制药今日主力资金净流出276万元,连续4日净流出,上一交易日主力净流出92万元,今日环比增加200.00%。近一年数据显示,该股主力连续4日净流出后,次日下跌概率为45.45%,平均跌幅为1.47%。该股近5个交易日下跌3.63%,主力资金累计净流出772万元,其中2个交易日为股价上涨时净流出;近20日主力资金累计净流出678万元,其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219162454a1faa6ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219162454a1faa6ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01530","BK1583","BK1593"],"gpt_icon":0},{"id":"2492452906","title":"三生制药(01530)注销库存股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2492452906","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492452906?lang=zh_cn&edition=full","pubTime":"2024-12-18 18:48","pubTimestamp":1734518889,"startTime":"0","endTime":"0","summary":"智通财经APP讯,三生制药(01530)发布公告,自2024年6月13日至2024年6月28日,根据2023年购回授权及2024年购回授权(视情况而定),公司于香港联合交易所有限公司进行了一系列股份购回,作为库存股份而持有。截至本公告日期,公司已购回合共2122.7万股股份作为库存股份,占截至本公告日期已发行股份总数的约0.89%(不包括库存股份)。该等库存股份已于本公告日期注销。于库存股份注销后,公司不再拥有任何库存股份,而已发行股份总数为23.96亿股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1593","BK1161","01530"],"gpt_icon":0},{"id":"2492979474","title":"三生制药12月18日主力资金流出92万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2492979474","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492979474?lang=zh_cn&edition=full","pubTime":"2024-12-18 16:15","pubTimestamp":1734509744,"startTime":"0","endTime":"0","summary":"12月18日, 三生制药股价涨0.66%,报收6.14元,成交金额1868万元,换手率0.13%,振幅1.15%,量比0.30。三生制药今日主力资金净流出92万元,连续3日净流出,上一交易日主力净流出278万元,今日环比减少66.91%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为58.82%,平均跌幅为2.82%。该股近5个交易日下跌1.12%,主力资金累计净流出1437万元,其中3个交易日为股价上涨时净流出;近20日主力资金累计净流出1246万元,其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218161605a1f7fe09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218161605a1f7fe09&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1593","BK1161","01530"],"gpt_icon":0},{"id":"2492672448","title":"南向资金12月16日净卖出三生制药192.90万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2492672448","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492672448?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:30","pubTimestamp":1734399017,"startTime":"0","endTime":"0","summary":"12月16日,南向资金减持三生制药192.90万股连续3日减持。截止当日收盘,港股通共持有三生制药62229.31万股,占流通股25.74%。三生制药近5个交易日下跌4.89%,港股通累计减持717.80万股;近20个交易日上涨5.98%,港股通累计减持1927.60万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217093154ab7dbdc6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217093154ab7dbdc6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01530","BK1583","BK1593"],"gpt_icon":0},{"id":"2490879301","title":"三生制药12月12日遭主力抛售940万元 环比增加900.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490879301","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490879301?lang=zh_cn&edition=full","pubTime":"2024-12-12 16:16","pubTimestamp":1733991403,"startTime":"0","endTime":"0","summary":"12月12日, 三生制药股价涨1.77%,报收6.34元,成交金额1.14亿元,换手率0.75%,振幅3.37%,量比1.82。三生制药今日主力资金净流出940万元,连续3日净流出,上一交易日主力净流出94万元,今日环比增加900.00%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为64.71%,平均跌幅为2.67%。该股近5个交易日上涨2.91%,主力资金累计净流出1604万元;近20日主力资金累计净流出2578万元,其中净流出天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212161748a1e885f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212161748a1e885f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","01530","BK1593"],"gpt_icon":0},{"id":"2490982557","title":"三生制药12月6日遭南向资金减持586.75万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490982557","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490982557?lang=zh_cn&edition=full","pubTime":"2024-12-09 09:30","pubTimestamp":1733707818,"startTime":"0","endTime":"0","summary":"12月6日,南向资金减持三生制药586.75万股。截止当日收盘,港股通共持有三生制药62825.15万股,占流通股25.99%。三生制药近5个交易日上涨8.22%,港股通累计减持1237.10万股;近20个交易日上涨1.81%,港股通累计减持3179.60万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209093120a1df0280&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209093120a1df0280&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","01530","BK1161","BK1583"],"gpt_icon":0},{"id":"2489447801","title":"三生制药12月5日遭南向资金减持776.20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2489447801","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489447801?lang=zh_cn&edition=full","pubTime":"2024-12-06 09:30","pubTimestamp":1733448611,"startTime":"0","endTime":"0","summary":"12月5日,南向资金减持三生制药776.20万股。截止当日收盘,港股通共持有三生制药63411.90万股,占流通股26.23%。港股通减持金额前五个股分别为美团-W、腾讯控股、药明生物、快手-W、理想汽车-W。三生制药近5个交易日上涨8.61%,港股通累计减持785.00万股;近20个交易日上涨2.49%,港股通累计减持2883.90万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206093141a1d7cfa9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206093141a1d7cfa9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01530","BK1583","BK1593"],"gpt_icon":0},{"id":"2489481485","title":"《大行》招商国际微升三生制药(01530.HK)目标价至9.81元 创新品种蓄势待发","url":"https://stock-news.laohu8.com/highlight/detail?id=2489481485","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489481485?lang=zh_cn&edition=full","pubTime":"2024-12-05 15:15","pubTimestamp":1733382900,"startTime":"0","endTime":"0","summary":"招商国际发表研报指,由于医保基金持续支持创新药,预期三生制药续约品种的价格将较为稳定,为其稳健增长提供支撑。招商国际亦指,三生制药在研管线推进顺利,多款创新品种已进入NDA或临床III期,因而预期新产品将自2026年开始逐步成为公司重要的增长引擎。另外,招商国际预计三生制药2024及2025财年收入,将分别按年增长12.8%及12.2%,料公司将维持30%的派息比例,故将其目标价轻微上调至9.81元,给予“买入”评级。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190604131534109_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190604131534109_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1402083/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01530"],"gpt_icon":0},{"id":"2489056261","title":"【券商聚焦】招银国际升三生制药(01530)目标价至9.81港元 料特比澳持续快速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2489056261","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489056261?lang=zh_cn&edition=full","pubTime":"2024-12-05 11:35","pubTimestamp":1733369709,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际发研报指,2024年国家医保目录结果公布,三生制药 特比澳成功续约并新增儿童ITP适应症、伊尼妥成功续约,盐酸纳呋拉啡口崩片新进入医保目录,用于改善血液透析患者的瘙痒症。该行认为,受益于适应症的拓展和渗透率的提升,特比澳在2025E有望持续快速增长。该行预期公司将维持30%的分红比例,目前股价对应2025E 股息率为4.5%。小幅上调目标价至9.81港元,对应9.8倍25年市盈率。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/M2ZiNmJjNGMwZDk5N2EzMzdhMmQ3YTNjNTY2NTQwOTU0NTAzNDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/M2ZiNmJjNGMwZDk5N2EzMzdhMmQ3YTNjNTY2NTQwOTU0NTAzNDA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949033","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"gpt_icon":0},{"id":"2489920106","title":"招财日报2024.12.5 Salesforce及三生制药公司点评","url":"https://stock-news.laohu8.com/highlight/detail?id=2489920106","media":"招银国际","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489920106?lang=zh_cn&edition=full","pubTime":"2024-12-05 11:18","pubTimestamp":1733368724,"startTime":"0","endTime":"0","summary":"公司点评Salesforce- 3QFY25业绩符合预期;Agentforce成为主要催化Salesforce公布了符合预期的3QFY25业绩:总收入同比增长8%至94.4亿美元,非GAAP净利润同比增长12%至23.2亿美元,均符合一致预期。基于Agentforce和Einstein,Salesforce目前已是全球最大的企业AI解决方案提供商之一,Einstein平台一周处理约2万亿AI相关请求。我们预计公司2024E和2025E收入将分别同比增长12.8%和12.2%,当前市值对应6.6倍2025E PE,估值极其吸引。我们预期公司将维持30%的分红比例,目前股价对应2025E 股息率为4.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205115508ab5eb261&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205115508ab5eb261&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRM","01530"],"gpt_icon":0},{"id":"2489517982","title":"南向资金12月4日净买入三生制药77.60万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2489517982","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489517982?lang=zh_cn&edition=full","pubTime":"2024-12-05 09:30","pubTimestamp":1733362212,"startTime":"0","endTime":"0","summary":"12月4日, 南向资金增持三生制药77.60万股,连续3日增持。截止当日收盘,港股通共持有三生制药64188.10万股,占流通股26.55%。三生制药近5个交易日上涨11.01%,港股通累计增持28.25万股;近20个交易日上涨6.90%,港股通累计减持2165.34万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205093125a1d4f905&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205093125a1d4f905&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1593","01530","BK1583"],"gpt_icon":0},{"id":"2488131335","title":"三生制药(01530)出现大手卖出78.2万股,成交价$6.36,涉资497.352万","url":"https://stock-news.laohu8.com/highlight/detail?id=2488131335","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488131335?lang=zh_cn&edition=full","pubTime":"2024-12-04 14:08","pubTimestamp":1733292480,"startTime":"0","endTime":"0","summary":"[大手成交]三生制药(01530)在下午02:08出现大手卖出,成交量为78.2万,成交价为港币$6.36,涉资497.352万。至目前为止,股价升0.949%,今日最高价为$6.46,而最低价为$6.27,总成交量为1.636千万股,总成交金额港币$1.043亿。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2412045685/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01530","BK1583","BK1593","BK1161"],"gpt_icon":0},{"id":"2488399179","title":"三生国健:三生制药及其下属企业持有公司的股份数并未发生变化","url":"https://stock-news.laohu8.com/highlight/detail?id=2488399179","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488399179?lang=zh_cn&edition=full","pubTime":"2024-12-03 18:00","pubTimestamp":1733220045,"startTime":"0","endTime":"0","summary":"证券之星消息,三生国健(688336)12月03日在投资者关系平台上答复投资者关心的问题。投资者:您好想了解下半年报的时候三生制药直接间接共持股有达到80%吗?最新看是只有40%三生国健董秘:尊敬的投资者您好,非常感谢您对公司的关注!三生制药及其下属企业持有公司的股份数并未发生变化。投资者:608项目公司能否可以按计划2024年内提报上市申请?三生国健董秘:尊敬的投资者您好,非常感谢您对公司的关注!公司的608项目已经按计划递交了上市申请并已获得受理。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120300032442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK1161","BK1593","688336","01530","BK0239"],"gpt_icon":0},{"id":"2488962929","title":"【券商聚焦】招银国际:多款重磅国产创新药纳入医保 基金收支有望改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2488962929","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488962929?lang=zh_cn&edition=full","pubTime":"2024-12-03 17:22","pubTimestamp":1733217761,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际发研指,MSCI中国医疗指数年初至今累计下跌17.6%,跑输MSCI中国指数30.1%。新版医保目录已公布,多款重磅国产创新药纳入,该行预期续约品种价格降幅较温和,体现医保基金持续大力支持创新药。今年9、10月份,基本医疗保险的收支结余显著改善。随着政策焦点转向刺激经济,该行认为医保基金收支状况有望大幅改善。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1948888","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","LU2045819591.USD","BK1207","BK1576","LU0588546209.SGD","LU1969619763.USD","LU0708995583.HKD","LU0320764599.SGD","LU2242644610.SGD","BK1161","LU0307460666.USD","02359","LU2488822045.USD","159992","06978","01530","01801","LU2125910500.SGD","BK1574","BK1588","BK1589","LU2328871848.SGD","BK1141","06160","LU0196878994.USD","BK1593","LU0052750758.USD","BK1500","06990","LU1046422090.SGD","02367"],"gpt_icon":0},{"id":"2488964127","title":"三生制药(01530)上涨10.02%,报6.37元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2488964127","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488964127?lang=zh_cn&edition=full","pubTime":"2024-12-03 15:24","pubTimestamp":1733210676,"startTime":"0","endTime":"0","summary":"12月3日,三生制药(01530)盘中上涨10.02%,截至15:24,报6.37元/股,成交2.03亿元。三生制药是一家主要致力于开发、生产和销售医药产品,产品包括重组人血小板生成素、肿瘤坏死因子α抑制剂以及重组人促红素等,销售市场涵盖国内以及斯里兰卡、多米尼加共和国和泰国等海外市场。此外,公司通过其子公司集思有限公司,香港三生医疗有限公司和沈阳三生制药有限责任公司也从事项目管理和咨询业务。截至2024年中报,三生制药营业总收入43.89亿元、净利润10.9亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/03152445949363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","01530","BK1593","BK1583"],"gpt_icon":0},{"id":"2488357962","title":"招银国际:医保持续支持创新 基金收支有望改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2488357962","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488357962?lang=zh_cn&edition=full","pubTime":"2024-12-03 15:22","pubTimestamp":1733210537,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,招银国际发布研报称,随着政策焦点转向刺激经济,医保基金收支状况有望大幅改善。2024年医保目录调整结果已公布,新增91种药品,医保支持创新。此外,医保局医保数据赋能商业保险公司推进的探索,未来高价创新药械或将通过医保与商业保险的协同获得更好的报销覆盖。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1997245094.SGD","BK1207","688235","01801","LU2328871848.SGD","BK0216","688271","LU0196878994.USD","BK0251","BK1593","01530","02367","LU2488822045.USD","BK1589","BK0239","06990","603259","LU0456842615.SGD","06978","BK1583","LU1969619763.USD","LU1997245177.USD","BK1161","BK1574"],"gpt_icon":0},{"id":"2488932873","title":"招商证券:维持三生制药(01530)“增持”评级 目标价上调至11港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488932873","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488932873?lang=zh_cn&edition=full","pubTime":"2024-12-03 10:42","pubTimestamp":1733193725,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,招商证券发布研究报告称,维持三生制药(01530)“增持”评级,目标价由10港元上调至11港元,相当于预测明年市盈率10倍。该行预计,三生制药的重要品种“特比澳”已在近期完成的国谈续约中,取得了温和的结果,而“丽美治”亦成功纳入医保目录。由于特比澳的温和续约结果,该行预计公司将在2025和2026财年,继续实现双位数的总收入增长。报告预计公司总体毛利率水平将在25至26财年期间,维持在86%水平(2024年上半年为86.5%),主要由于“特比澳”价格将在期间维持平稳。该行指出,三生制药目前股价相当于预测2025和2026财年市盈率各5倍,处于历史市盈率估值区间的低位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219476.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01530"],"gpt_icon":0},{"id":"2488951030","title":"三生制药早盘涨超5% 长江证券首次覆盖给予“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2488951030","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488951030?lang=zh_cn&edition=full","pubTime":"2024-12-03 10:31","pubTimestamp":1733193060,"startTime":"0","endTime":"0","summary":" 三生制药早盘上涨5.18%,现报6.09港元,成交额6464.49万港元。 此前,长江证券发布研究报告称,首次覆盖三生制药,给予“增持”评级,预计2024-2026年公司实现营业收入90.90亿元、102.51亿元、117.11亿元,归母净利润21.73亿元、24.43亿元、27.27亿元,当前股价对应的PE倍数分别为6.9X、6.1X、5.5X。公司较早布局大健康领域,生发、皮肤科产品具备先发优势,同时肿瘤、肾科等多个优势领域产品体系成熟。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-12-03/doc-incycyix5026171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01530","000783"],"gpt_icon":0},{"id":"2488093143","title":"三生制药盘中异动 快速上涨5.01%报6.080港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488093143","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488093143?lang=zh_cn&edition=full","pubTime":"2024-12-03 10:06","pubTimestamp":1733191608,"startTime":"0","endTime":"0","summary":"2024年12月03日早盘10时06分,三生制药股票出现波动,股价大幅拉升5.01%。截至发稿,该股报6.080港元/股,成交量751.25万股,换手率0.31%,振幅5.01%。资金方面,该股资金流入2770.77万港元,流出834.394万港元。三生制药股票所在的药品行业中,整体涨幅为0.09%。其相关个股中,三爱健康集团、先声药业、三生制药涨幅较大,振幅较大的相关个股有先声药业、三生制药、九源基因,振幅分别为7.16%、4.84%、3.30%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203100648abf15fd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203100648abf15fd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01530","BK1583","BK1161","BK1593"],"gpt_icon":0},{"id":"2488120931","title":"港股异动 | 三生制药(01530)现涨近5% 机构预计特比澳国谈续约结果温和 丽美治成功纳入医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2488120931","media":"智通财经","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488120931?lang=zh_cn&edition=full","pubTime":"2024-12-03 10:06","pubTimestamp":1733191575,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,三生制药现涨近5%,截至发稿,涨4.84%,报6.07港元,成交额4242.82万港元。招商证券发布报告称,预计三生制药的重要品种“特比澳”已在近期完成的国谈续约中,取得了温和的结果,而“丽美治”亦成功纳入医保目录。由于特比澳的温和续约结果,该行预计公司将在2025和2026财年,继续实现双位数的总收入增长。报告预计公司总体毛利率水平将在25至26财年期间,维持在86%水平,主要由于“特比澳”价格将在期间维持平稳。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","01530","BK1161","BK1583"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.3sbio.com","stockEarnings":[{"period":"1week","weight":-0.0379},{"period":"1month","weight":0.0627},{"period":"3month","weight":0.0702},{"period":"6month","weight":0.0447},{"period":"1year","weight":-0.0687},{"period":"ytd","weight":-0.1566}],"compareEarnings":[{"period":"1week","weight":-0.0316},{"period":"1month","weight":0.0045},{"period":"3month","weight":0.0818},{"period":"6month","weight":0.0956},{"period":"1year","weight":0.1889},{"period":"ytd","weight":0.1587}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"三生制药是一家主要从事开发、生产、营销及销售医药产品的投资控股公司。该公司的主要产品包括重组人血小板生成素产品,肿瘤坏死因子α抑制剂产品以及重组人促红素等。产品以特比澳,益赛普,益比奥,以及赛博尔等品牌销售。该公司在国内市场和斯里兰卡、多米尼加共和国及泰国等海外市场销售产品。该公司的子公司包括集思有限公司,香港三生医疗有限公司和沈阳三生制药有限责任公司。该公司通过其子公司还从事项目管理及咨询业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":-0.00277},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.015935},{"month":3,"riseRate":0.777778,"avgChangeRate":0.064866},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.015967},{"month":5,"riseRate":0.666667,"avgChangeRate":0.057469},{"month":6,"riseRate":0.777778,"avgChangeRate":0.012147},{"month":7,"riseRate":0,"avgChangeRate":-0.078897},{"month":8,"riseRate":0.4,"avgChangeRate":-0.006345},{"month":9,"riseRate":0.6,"avgChangeRate":0.027364},{"month":10,"riseRate":0.4,"avgChangeRate":-0.022784},{"month":11,"riseRate":0.7,"avgChangeRate":0.064392},{"month":12,"riseRate":0.5,"avgChangeRate":-0.026884}],"exchange":"SEHK","name":"三生制药","nameEN":"3SBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生制药,01530,三生制药股票,三生制药股票老虎,三生制药股票老虎国际,三生制药行情,三生制药股票行情,三生制药股价,三生制药股市,三生制药股票价格,三生制药股票交易,三生制药股票购买,三生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}